Tagged Articles

Invokana side effects 23 articles

Number of Invokana side effects lawsuits growing

Johnson & Johnson and its subsidiary Janssen Pharmaceuticals may be rolling in revenue from sales of its new type 2 diabetes drug Invokana, but they may soon be rolling in lawsuits over Invokana side effects. Complaints include reports of kidney damage, heart disease and ketoacidosis, a condition in which too much acid builds up in the blood. One of the lawsuits was filed on behalf Cornelius Benjamin, a South Carolina man who allegedly suffered a stroke and kidney damage after he was prescribed Invokana. He died two months later, in June 2013. Alabama resident Robert Partington is suing because he claims ... Read More

Invokana combination drug studied as possible obesity treatment

Combining a prescription appetite suppressant with the type 2 diabetes drug Invokana can produce significant weight loss in diabetic patients, according to a study presented at the American Diabetes Association Scientific Sessions. “Both of these drugs have been used singly for weight loss and have been somewhat effective, but perhaps have not met the goals that we would like to see for weight loss,” said Priscilla Hollander, MD, with Baylor Medical Center. Her study evaluated the efficacy and safety of adding 15 mg of phentermine to 300 mg of Invokana in a study involving 334 adults with type 2 diabetes ... Read More

Invokana cardiovascular data much anticipated by analysts

Long-term cardiovascular data on the type 2 diabetes drug Invokana is among the “three most important data releases and FDA decisions in the next nine months,” according to The Motley Fool analysts. Like all drug manufacturers of type 2 diabetes medications approved in recent years, Johnson & Johnson’s Janssen Pharmaceuticals was ordered to collect post-market data regarding cardiovascular events with Invokana. Analysts expect the results to be similar to that of Boehringer Ingelheim’s diabetes drug Jardiance, which was found to reduce cardiovascular-related death in type 2 diabetics at high risk for cardiovascular events. Both Jardiance and Invokana are in a ... Read More

Janssen files motion to send Invokana lawsuits to courts outside PA

Johnson & Johnson subsidiary Janssen Pharmaceuticals is looking to send Invokana lawsuits piling up in Philadelphia to other courts, starting with a forum non conveniens motion seeking to have plaintiff Joyce Jeffries’ case transferred from the Philadelphia Court of Common Pleas to the plaintiff’s former home state of Tennessee. Jeffries, like dozens of others, have filed lawsuits alleging Janssen did not adequately warn of Invokana side effects including kidney failure and ketoacidosis, a buildup of acid in the blood. Invokana, known chemically as canagliflozin, is in a class of type 2 diabetes medications known as SGLT2 inhibitors. Jeffries’ lawsuit alleges ... Read More

Invokana effective in type 1 diabetics but side effects persist

Johnson & Johnson’s subsidiary Janssen Pharmaceuticals announced promising efficacy results from a Phase II study showing improvements in blood sugar levels in type 1 diabetics who were treated with its type 2 diabetes drug Invokana. But the news was dampened when the Food and Drug Administration (FDA) issued new warnings for Invokana the same week as the pharmaceutical company’s announcement. Invokana, known chemically as canagliflozin, is in a class of diabetes drugs known as SGLT2 inhibitors. The medication is approved to treat patients with type 2 diabetes, but Janssen’s latest study focused on patients with type 1 diabetes, formerly known ... Read More

Drug maker considers expanding Invokana use despite side effects

Johnson & Johnson’s Invokana is a rising star in the type 2 diabetes market, and sales of the drug will continue to grow if the pharmaceutical giant can expand the indication for the drug. Currently, the drug company is testing the medication on patients with type 1 diabetes, and Phase II study results show Invokana with insulin beat a placebo-insulin combination drug at lowering both mean glucose levels and glycemic variability, and kept participants within their target glucose ranges longer. That data was presented at the American Diabetes Association’s annual meeting. “Less swings, less variability, more time in target range ... Read More

Type 2 diabetes market expected to double by 2025

Worldwide sales of type 2 diabetes treatments are expected to nearly double from $31.2 billion in 2015 to $58.7 billion by 2025, a compound annual growth rate of 6.5 percent, according to research and consulting firm GlobalData. The countries most affected are the U.S., France, Germany, Italy, Spain, the UK, Japan, China and India. GlobalData says the growth can be attributed to the dramatic increase in the number of people with the disease and related comorbidities that have prompted a more aggressive approach in treatments including the use of multi-drug therapies. Also fueling the anticipated increase in diabetes treatment sales ... Read More

Elderly patients more vulnerable to Invokana side effects

A pooled analysis of adverse event reports in patients taking the type 2 diabetes medication Invokana found that patients 75 years and older were more likely to suffer Invokana side effects compared to patients younger than 75 treated with the drug. The study, published in The Journal of the American Geriatrics Society, was designed to compare the efficacy and safety of Invokana in younger patients versus elderly patients. Researchers measured HbA1c, fasting blood glucose, blood pressure and body weight for participants. Efficacy was evaluated using pooled data from six randomized, double-blind, placebo-controlled studies. Safety was assessed based on adverse event ... Read More

Invokana sales climb despite new or stronger side effects warnings

Blockbuster drugs – ones that generate more than $1 billion in sales in one year – are few and far between. Among the drugs that reach this level, a few have the potential to see their sales soar even higher. Financial analysts with Motley Fool have selected four medications that are enjoying booming sales, and they anticipate the growth to continue. These include the prostate cancer drug Xtandi, the blood thinner Eliquis, the multiple myeloma treatment Revlimid, and the type 2 diabetes medication Invokana. Reaching blockbuster status is an achievement on its own, but it is particularly notable in a ... Read More

Invokana plagued by new side effects since its FDA approval

It’s been three years since the Food and Drug Administration (FDA) approved Johnson & Johnson’s Janssen Pharmaceutical’s drug Invokana (canagliflozin) as a treatment for type 2 diabetes. Since then, the FDA and other drug regulators have issued numerous warnings over new Invokana side effects that have emerged outside initial clinical trials. Invokana was the first drug approved in the United States in a class known as sodium glucose cotransporter 2 (SGLT2) inhibitors. Prescriptions for the drug have since soared, generating hundreds of millions in revenue. In May 2015, the FDA issued a Safety Communication warning that Invokana and two other ... Read More